A study of serum biomarkers associated with relapse of cervical cancer
2012 (English)In: Anticancer Research, ISSN 0250-7005, E-ISSN 1791-7530, Vol. 32, no 11, 4913-22 p.Article in journal (Refereed) Published
BACKGROUND/AIM: To discover candidate protein biomarkers in the serum of patients with cervical cancer that differentiate between patients with relapse from those who are tumor-free after primary treatment with (platinum-based chemo-) radiation.
PATIENTS AND METHODS: Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) with cation exchange (CM10) and hydrophobic/reverse-phase (H50) was used to examine 44 serum samples from patients with advanced cervical cancer, primarily treated with (platinum-based chemo-) radiation.
RESULTS: Ten candidate biomarkers were identified in the serum of 34 patients. Six candidate markers were elevated in patients with no relapse and four were elevated in patients with relapse [p=0.007-0.11; area under the curve (AUC)=0.70-0.75]. Masses of candidate biomarkers ranged from 2,022 to 116,165 Da.
CONCLUSION: Patients with relapse from primary advanced cervical cancer exhibit different serum protein expression profiles from those with no relapse.
Place, publisher, year, edition, pages
2012. Vol. 32, no 11, 4913-22 p.
Cancer and Oncology
IdentifiersURN: urn:nbn:se:oru:diva-56898ISI: 000311524500037PubMedID: 23155260ScopusID: 2-s2.0-84872659639OAI: oai:DiVA.org:oru-56898DiVA: diva2:1085569